

ISSN 0974-3618 (Print)
0974-360X (Online)

www.rjptonline.org



RESEARCH ARTICLE

Compounds Derived from Calamansi Orange Peel Exhibit Potency as HER2 Inhibitors in Breast Cancer

Audie Joscelino Huang, Windra Prayoga, Yulanda Antonius*

Master of Biotechnology, Faculty of Biotechnology, University of Surabaya, Surabaya, Indonesia.

*Corresponding Author E-mail: yulandaantonius@staff.ubaya.ac.id

ABSTRACT:

Breast cancer indicated uncontrollably proliferation and spread of cells that related to HER2 overexpression. In 2020, Indonesia showed the highest prevalence of breast cancer with 65.858 cases. Several therapeutic methods had been carried out, including chemotherapy, and radiation therapy. However, it induced various side effect during the treatment. Herbs are considered as an alternative therapy for treatment. The calamansi orange peel is considered as a waste, yet it known for containing various therapeutic properties. The therapeutic efficacy of calamansi orange peel in the treatment of breast cancer requires more investigation. Thus, the purpose of this study was to determine the potency of compounds from calamansi orange's peel against breast cancer. Five compounds of calamansi orange peel were collected as a sample from PubChem database. Those compounds were addressed for several analysis, such as analysis of biological activity by using PASS Online, toxicity analysis by using ProTox 3.0, and drug-likeness analysis by using SWISS ADME. Furthermore, HER2 protein was selected as a protein target. The interaction between sample compounds and protein target was simulated through molecular docking analysis by using PyRx software and continued with amino acid residue analysis. Moreover, further analysis toward HER2 protein was conducted through protein-protein network analysis using STRING database. Result showed that all sample compounds had biological activity related to anticancer activity, such as antineoplastic, apoptosis agonist, and anti-inflammatory with Pa score 0.5 – 0.7. Moreover, the drug-likeness analysis according to Lipinski's rule of five depicted that all sample compounds fulfil the required parameters. Those compounds also demonstrated low toxicity level with average toxicity class 4 and 5. Interaction of compounds toward protein target demonstrated all sample compound had comparable binding affinity score as compared to native ligand and reference ligand. In brief, 3-Isopropenyl-5,5-Dimethyl-Cyclopentene had binding affinity -6,5 kcal/mol. The native ligand and sample compound both shared amino acid residues in Ala751, Met774, Ser783, Leu785, and Thr862. Additionally, HER2 protein depicted a link to the immune system, and cell proliferation pathway. Thus, compounds derived from calamansi orange peel considered had potential therapeutic effect for breast cancer treatment.

KEYWORDS: Binding affinity, Breast cancer, Calamansi orange, HER2, Molecular docking.

INTRODUCTION:

Cancer is characterized as an abnormal condition of cells that have uncontrolled division throughout the body¹. According to World Health Organization (WHO), cancer caused 8.9 million deaths in the world with 70% of instances originated from developing countries^{2,3}. The breast cancer cases increased by the time which data from 2020 showed that it also responsible for 685.000 deaths in worldwide⁴. In Indonesia, the prevalence of breast cancer is increased with a total of 396, 914 cases, and 234, 511 deaths in

Received on 14.10.2024 Revised on 22.02.2025
Accepted on 16.05.2025 Published on 01.10.2025
Available online from October 04, 2025
Research J. Pharmacy and Technology. 2025;18(10):4942-4948.
DOI: 10.52711/0974-360X.2025.00714
© RJPT All right reserved

This work is licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike 4.0
International License. Creative Commons License.



2020^{5,6}. Several treatments of breast cancer therapy had been widely used, including chemotherapy, radiation therapy, and hormone therapy^{7,8}. However, those treatments are known for causing various side effects, such as urination disorders, fatigue, vomiting, weight loss, anaemia, and others. Apart from that, all those treatments are also needing a high cost. Thus, an alternative treatment and therapy that affordable are needed⁹.

Herbs is considered as an alternative therapy for disease. The herbs therapy utilized the plant's compound with research approach^{10,11}. Oranges are well-known as a fruit with huge health benefit. Previous studies found that citrus-related plants had various bioactivity, including quercetin and flavonoid compound in lime¹², alkaloid, flavonoid, phenolic, and terpenoid compound in kaffir lime¹³, tangeretin and kaempferol in tangerine^{14,15}, and terpenoid compound on lime berry¹⁶. In brief, calamansi orange (*Citrus microcarpa*) also known for containing various compounds, namely monoterpene, sesquiterpene, ester, ketone, alcohol, aldehyde, flavonoid, limonoid and phytosterol groups of compounds¹⁷. However, most of calamansi orange peel are not commonly utilized and become a waste.

HER2 or receptor tyrosine-protein kinase erbB-2, is a transmembrane glycoprotein measuring 185 kDa. HER2 bind with HER1 and/or HER3 to initiate phosphorylation process. It related to the cell division, survivability process, migration, adhesion, and angiogenesis. Simultaneously, it also influences the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT), Phosphatidylinositol-3-kinase (PI3K/AKT), and RAS/RAF/MEK/ERK pathways^{18,19,20}. Heterodimers in HER receptor protein family had more signal potency compared to homodimers structure. However, there is also a possibility that HER2 homodimer formed when the HER2 is overexpressed. The overexpression of HER2 result in uncontrol cell division, migration, survivability, and signalling pathway activity^{21,22,23}. Therefore, this study aimed to identify compounds derived from calamansi orange that had potential ability as an inhibitor of HER2 in breast cancer. The research analysis carried out through protein network and drug discovery analysis.

MATERIALS AND METHODS:

Ligand Preparation:

Simplified Molecular Input Line Entry System (SMILE) of five compounds derived from calamansi orange peel (*Citrus microcarpa*), namely: D-Limonene (CID: 440917), R-(+)-Citronellal (CID: 75427), 3-Isopropenyl-5,5-Dimethyl-cyclopentene (CID: 564576), Gamma terpinene (CID: 7461), Citronellol (CID: 8842) was

chosen as reference ligand and 03Q was utilized as native ligand. The 3D structure of sample compounds, reference ligand, and native ligand were collected in. sdf format.

Protein Preparation:

HER2 protein 3D Structure sample (PDB: 3PP0) was taken from PDB database (<https://www.rcsb.org/>) in .pdb format. Furthermore, the water molecule from the protein sample was eliminated through Discovery Studio software. The polar hydrogen was added by using PyMOL Software.

Biological Activity Analysis:

The biological activity of sample compounds, Lapatinib (reference ligand), and 03Q (native ligand) were identified by using Prediction of Biologically Active Substances (PASS) Online (<http://www.way2drug.com/passonline/>). Several biological activities related to breast cancer mechanisms were selected, such as anti-inflammatory, apoptosis agonist, and antineoplastic in breast cancer. The results of biological activity determined based on the Probability of Activity (Pa) and Probability of Inactivity (Pi) score on a scale of 0-1. The Pa score in range 0.5 - 0.7 were addressed for further analysis²⁴.

Toxicity Analysis:

The toxicity analysis of sample compounds and reference ligand were carried out by using ProTox 3.0 (<https://tox.charite.de/protox3/>). It aimed to classify the toxicity of compounds using Globally Harmonized System (GHS) and toxicity prediction based on the Lethal Dose (LD50) in mg/kg. Additionally, toxicity prediction as hepatotoxicity, immunogenicity, and cytotoxicity were also measured in range of scale 0-1²⁵.

Drug-likeness Analysis:

The drug-likeness analysis was carried out by using SWISS ADME (<http://swissadme.ch>). The analysis was addressed based on the Lipinski's rule of five parameters, including: molecular Weight (MW) in 500 g/mol, number of donor hydrogen (5), number of acceptor hydrogen (10), and lipophilicity (MlogP) in 4.15. The analysis aimed to determine by the absorption ability of compounds into the human body²⁶.

Molecular Docking Analysis:

All compound samples were then addressed for simulation of interaction toward HER2 protein through molecular docking. The analysis was carried out utilizing specific docking method in PyRx software by selecting the active site of HER2 protein as the target with adjusted grid box coordinate (X = 16.94 Å; Y = 15.18 Å; Z = 21.62 Å) with the center coordinates at (X = 19.01 Å; Y = 18.34 Å; Z = 27.51 Å). The interaction

of sample compounds and protein were measured as binding affinity score (kcal/mol) that compared to reference ligand, and native ligand. In brief, the binding affinity values were acquired from RMSD model 0, and the models were saved in .pdbqt format for visualization of ligand-protein interactions.

Analysis of Amino Acid Residues:

The complex of sample compound and HER2 protein were addressed for amino acid residues analysis by using Discovery Studio software. The interaction type of amino acid residues was compared to the reference ligand and native ligand.

Protein-Protein Interaction Network (PPIN) Analysis:

All sample compounds were analysed by using STITCH database (<http://stitch.embl.de/>) to explore its interaction towards various protein. Furthermore, those various protein were subjected for further analysis by using STRING database (<https://string-db.org/>). It aimed to identify the protein interaction related to cancer pathway through gene ontology (GO) and false discovery (FDR) rate.

RESULT:

All the sample compounds derived from calamansi orange peel possessed biological activity related to cancer, including anti-inflammatory, apoptosis agonist, and antineoplastic in breast cancer. In brief, D-Limonene and citronellol had high anti-inflammatory activity with Pa score more than 0.5. All sample compounds also demonstrated the apoptosis agonist

activity with high Pa score, except gamma terpinene which depicted Pa score in 0.348. However, only D-limonene that showed high Pa score in antineoplastic activity. Whilst, lapatinib which served as a control is specifically demonstrated the bioactivity as antineoplastic in breast cancer (Figure 1).




Figure 1. Predicted biological activity of compounds derived from calamansi orange peel

Further identification in toxicity analysis showed that all sample compounds and reference ligand are classified into toxicity class 4 and 5. Moreover, further analysis demonstrated that all sample compound also possessed inactive probability for hepatotoxicity, immunotoxicity, and cytotoxicity. Therefore, the sample compounds are considered as safe (Table 1).

Table 1. Predicted toxicity properties of compounds derived from calamansi orange peel

Compounds	LD50 (mg/kg)	Toxicity Class	Accuracy (%)	Probability		
				Hepatotoxicity	Immunotoxicity	Cytotoxicity
D-Limonene	4400	5	100	0.76 (Inactive)	0.95 (Inactive)	0.82 (Inactive)
R-(+)-Citronellal	2420	5	100	0.70 (Inactive)	0.99 (Inactive)	0.82 (Inactive)
3-Isopropenyl-5,5-Dimethyl-Cyclopentene	3850	5	69.26	0.81 (Inactive)	0.96 (Inactive)	0.77 (Inactive)
Gamma Terpinene	2500	5	100	0.83 (Inactive)	0.98 (Inactive)	0.82 (Inactive)
Citronellol	3450	5	100	0.84 (Inactive)	0.99 (Inactive)	0.86 (Inactive)
Lapatinib (Reference ligand)	1500	4	23	0.80 (Active)	0.96 (Active)	0.76 (Active)

Table 2. The drug-likeness characteristics of calamansi orange peel derived compounds

Compounds	Lipinski Rule of Five				Violation
	H-Bond Donor ≤ 5	H-Bond Acceptor ≤ 10	Molecular Weight ≤ 500 g/mol	MLOGP ≤ 4.15	
D-Limonene	0	0	136.23	3.27	0
R-(+)-Citronellal	0	1	154.25	2.59	0
3-Isopropenyl-5,5-Dimethyl-Cyclopentene	0	0	136.23	3.27	0
Gamma Terpinene	0	0	136.23	3.27	0
Citronellol	1	1	156.27	2.70	0
Lapatinib (Reference ligand)	2	8	581.06	3.44	1
03Q (Native ligand)	2	9	493.87	2.46	0

After all the sample compounds are demonstrated the biological activity related to anti-cancer mechanism and showed safety, further analysis to determine the drug-likeness properties are conducted. As compared to

Lapatinib (reference ligand), result depicted that all selected compounds derived from calamansi orange peel fulfil the required parameters of Lipinski rule of five. All sample compounds did not demonstrate any

violation towards molecular weight threshold, hydrogen donor number, hydrogen acceptor number, and lipophilicity properties (Table 2).

All sample compounds and reference ligand are depicted bind into the same binding site location as native ligand (Figure 2). It also indicated by similar amino acid residues which shared between sample compounds, reference ligand, and native ligand. In specific, shared hydrophobic interaction and van der Waals interaction, including Leu726, Ala751, Met774, Ser 783, Leu785, Leu852, and Thr862 (Table 3). However, the binding affinity score of sample compounds are still higher than native ligand. In brief, those binding affinity score are almost similar to reference ligand with score -6.9 kcal/mol (Table 4).




Figure 2. Complex of HER2 protein and compounds derived from calamansi orange peel: D-Limonene (Yellow), R-(+)-Citronellal (Pink), 3-Isopropenyl-5,5-Dimethyl-Cyclopentene (Cyan), Gamma Terpinene (Orange), dan Citronellol (Grey), 03Q (Red), and Lapatinib (Dark Blue)

Table 3. Amino acid residues and chemical bond of compounds derived from calamansi orange peel toward HER2 Protein

Compounds (Ligand)	Hydrogen Bond	Hydrophobic Bond	Halogen Bond	Van Der Waals Bond	Unfavorable Bond
D-Limonene	-	Val734, Ala751, Lys753, Met774, Leu785, Leu796, Phe864	-	Glu770, Ser783, Thr798, Thr862, Asp863	-
R-(+)-Citronellal	Asp863: 3.87 Å	Ala771, Met774, Leu785, Leu796, Phe864	-	Lys753, Glu770, Ser783, Thr798, Thr862	-
3-Isopropenyl-5,5-Dimethyl-Cyclopentene	-	Lys753, Ala771, Met774, Leu785, Leu796, Phe864	-	Glu770, Ser783, Thr798, Thr862, Asp863	-
Gamma Terpinene	-	Leu726, Val734, Ala751, Lys753, Leu852	-	Thr798, Leu800, Met801, Gly804, Thr862, Asp863	-
Citronellol	Ala751: 4.33 Å Lys753: 5.01 Å Leu796: 4.82 Å	Ala771, Met774, Leu785, Phe864	-	Val734, Ile752, Glu770, Ser783, Val797, Thr798, Thr862, Asp863	-
Lapatinib (Reference ligand)	Ser728: 5.10 Å Gln799: 6.41 Å Arg849: 4.72 Å	Leu726, Val734, Ala751, Lys753, Met774, Leu785, Leu796, Thr798, Cys805, Leu852	Glu770, Asp863	Gly727, Gly729, Ala771, Ser783, Leu800, Gly804, Asn850, Thr862, Phe864, Gly865	Met801
03Q (Native ligand)	Ser728: 4.90 Å Gln799: 6.96 Å	Leu726, Ala751, Met774, Leu785, Leu852, Phe864	Glu770, Leu796	Gly729, Val734, Ile752, Lys753, Ala771, Ser783, Val797, Thr798, Gln799, Gly804, Cys805, Asn850, Thr862, Asp863	Met801, Arg849

Table 4. Binding affinity score of compounds derived from calamansi orange peel toward HER2 Protein

Compounds	Binding Affinity (kcal/mol)
D-Limonene	-6.5
R-(+)-Citronellal	-6.2
3-Isopropenyl-5,5-Dimethyl-Cyclopentene	-6.6
Gamma Terpinene	-6.5
Citronellol	-6.4
Lapatinib (Reference ligand)	-6.9
03Q (Native ligand)	-11.1

HER2 protein as a target protein had essential role in breast cancer pathway. Protein interaction network demonstrated that HER2 protein closely related to regulation of cell population proliferation. HER2 protein connected with most protein in the network and low FDR score about 1.13e-18. Furthermore, protein interaction network also depicted the relation with regulation of apoptotic process (Figure 3, Table 5).




Figure 3. Protein-protein interaction pathway related to breast cancer: Regulation of cell population proliferation (red) and Regulation of Apoptotic Process (Blue)

Table 5. Biological process of proteins related to breast cancer

GO-term	Biological Process	Proteins	False Discovery Rate (FDR)
GO:0042127	Regulation of cell population proliferation	SHC4, CBLB, SHC1, GAB2, ERBB4, KDR, FGFR2, ERBB3, SRC, PIK3CA, PIK3CD, PGR, IGF1R, EGFR, STAT3, AKT1, COL18A1, NOS3, STAT5A, ESR1, TP53, AKT2, MDM2, FOXO3, ATM, CDKN1A, FOXO1, KAT2B	1.13e-18
GO:0042981	Regulation of apoptotic process	PIK3R3, CBL, SHC1, ERBB4, ERBB3, KDR, FGFR2, SRC, PIK3CA, PIK3CD, PIK3R1, IGF1R, EGFR, AKT1, NOS3, ESR1, TP53, AKT2, ATM, FOXO3, MDM2, MCL1, FOXO1	1.36e-15

DISCUSSION:

Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor that belongs to epidermal growth factor receptor (EGFR) family. HER2 is expressed at low rate in normal tissues by starting the intracellular pathways that support cell survival and proliferation^{27,28}. However, the overexpression of HER2 could lead to uncontrolled cell growth, such as in breast cancer. Approximately, about 20% of breast cancer had overexpression of HER2 and lead to disease progression²⁷. Therefore, the use of targeted inhibitors is essential to manage the aggressive cancer and improve the patient outcomes. Lapatinib is small molecule that specifically targeting HER2 protein. By inhibiting the HER2 receptors, lapatinib blocks downstream signal pathway that promote cell proliferation and cell survival in cancer²⁹.

Through the simulation of the ligand-target protein interaction, the molecular docking simulation plays a critical role in the identification of potential inhibitors³⁰. In this research, all sample compound derived from calamansi orange peel determined as a ligand and simulated the interaction toward HER2 protein. Most of sample compounds had binding affinity score that almost similar to Lapatinib as reference ligand supported by hydrogen bond and hydrophobic bond³¹. Nevertheless, it had significant score of binding affinity as compared to native ligand with -11.1kcal/mol, shows that all ligands have stable and strong energy to bind towards HER2 protein³². Moreover, there are similarities amino acid residues in hydrophobic and Van der Waals bonds between the sample ligands, native ligands and reference ligands, including: Leu 726, Ala 751, Met 754, Ser 783, Leu 785, Leu 852, and Thr 862 which indicate that the sample ligand's have a similar opportunity to native ligand and reference ligand as HER2 inhibitor³³.

Sample compounds have been extensively studied as potential alternative therapies for breast cancer. Further investigations are necessary to fully validate the herbal compound efficacy and its activity. The results of PASS Online analysis determined based on Pa score and the Pi score (Figure 1). The Pa score showed the probability of compound for possessed certain biological activity, while Pi value shows the opportunity of a compound to be inactive to carry out certain biological activity. The Pa score that less than 0.5 indicated poor potential, 0.5 <

Pa <0.7 suggested moderate potential, and Pa score greater than 0.7 indicated high potency of compound in certain biological activity³⁴. All the sample compound derived from calamansi orange peel showed high potential biological activity as anti-inflammatory agent and apoptosis agonist. Whilst, only D-limonene showed high potential in antineoplastic activity. All those compounds possessed high potency as compared to Lapatinib. Those compounds also classified in low toxicity class and less harmful toward cells and liver organ compared to Lapatinib, which suggests all ligands were non-toxic and had no risk to cause cytotoxicity, hepatotoxicity, and immunotoxicity³⁵.

In the context of drug pharmacokinetics, the mechanisms of Absorption, Distribution, Metabolism, and Excretion (ADME) are strongly linked to Lipinski's Rule of Five^{36,37}. Although the primary focus of ADME is pharmacokinetics—what the body does to a medication—it is crucial to comprehend the interaction of ADME with pharmacodynamics, which is termed as what the drug does to the body, including drug administration, circulation, chemical alteration and elimination mechanism in the body³⁸. All the compound derived from calamansi orange peel fulfil the threshold of required parameters. It is essential for developing the medicine for oral administration. Furthermore, the STRING result demonstrates that the calamansi ligand, which interacts with the HER2 protein, is involved in the inhibition mechanism and influences the regulation of the ERBB pathway, protein kinase at the receptor, cell proliferation, apoptotic process, and immune system. The ligand which interacts with the HER2 protein will cause the entire signalling pathway under HER2 will be inhibited. As a result, the active number of HER2 will decrease because of the inhibition. Despite this, the compounds derived from calamansi oranges peel is still need to be updated and analysed. Moreover, *in vitro* and *in vivo* research must be conducted further to confirm the results³³.

CONCLUSION:

Various compounds derived from calamansi oranges peel (*Citrus microcarpa*) offer a promising alternative therapy for breast cancer due to their potency as an inhibitor of HER2 protein compared to Lapatinib. Furthermore, the compounds demonstrated bioactivity related to anti-cancer, such as anti-inflammatory activity

and apoptosis agonist activity. Additionally, it also showed safety and potency in drug pharmacokinetics.

CONFLICT OF INTEREST:

There are no disclosed conflicts of interest associated with this study by the authors.

ACKNOWLEDGMENTS:

The authors thank the University of Surabaya for assisting with the research.

REFERENCES:

- Singh HV et al. Breast Cancer: From Etiology to Therapeutic Interventions. *Research Journal of Pharmacology and Pharmacodynamics*. 2024; 16(3): 199-207. doi: 10.52711/2321-5836.2024.00034
- Mattiuzzi C, Lippi G. Current Cancer Epidemiology. *Journal of Epidemiology and Global Health*. 2019; 9(4): 217-22. doi: 10.2991/jegh.k.191008.001
- Kshirsager SS et al. Novel Molecule of Protein Tyrosine Kinase Enzyme Inhibitor in Treatment of Breast Cancer: Neratinib Maleate. *Asian Journal of Research in Pharmaceutical Sciences*. 2020; 10(2): 100-2. doi: 10.5958/2231-5659.2020.00019.3
- Yansen IA et al. Potential of Bidara Leaf as Adjunctive Therapy against Breast Cancer Cell Line: A Review. *Research Journal of Pharmacy and Technology*. 2023; 16(11): 5532-5. doi: 10.52711/0974-360X.2023.00895
- Andinata B et al. A Comparison of Cancer Incidences Between Dharmas Cancer Hospital and GLOBOCAN 2020: A Descriptive Study of Top 10 Cancer Incidences. *Indonesian Journal of Cancer*. 2023; (2): 119-22. doi: 10.33371/ijoc.v17i2.982
- Prihantono et al. Cancer Incidence and Mortality in Tertiary Hospital in Indonesia: An 18-Year Data Review. *Ethiopian Journal of Health Science*. 2023; 33(3): 515-22. doi: 10.4314/ejhs.v33i3.15
- Soni A et al. In-vitro Cytotoxic Activity of Plant Saponin Extracts on Breast Cancer Cell-Line. *Research Journal of Pharmacognosy and Phytochemistry*. 2017; 9(1): 17-22. doi: 10.5958/0975-4385.2017.00003.6
- Srivastava S, Kumar A. Breast Cancer Survivorship among Indian Women: An Overview. *Asian Journal of Nursing Education and Research*. 2022; 12(3): 262-6. doi: 10.52711/2349-2996.2022.00056
- Widyananda MH et al. Exploration of potentially bioactive compounds from fingerroot (*Boesenbergia rotunda* L.) as inhibitor of atherosclerosis-related proteins (CETP, ACAT1, OSC, sPLA2): An in silico study. *Jordan Journal of Pharmaceutical Science*. 2023; 16(3): 550-64. doi: 10.35516/jjps.v16i3.1609
- Suhargo L et al. Antidiabetic Activity of Daun Wungu (*Graptophyllum pictum* L. Griff) Extract via Inhibition Mechanism of TNF- α , IL-6, and IL-8: Molecular Docking and Dynamic Study. *Research Journal of Pharmacy Technology*. 2023; 16(5): 2291-6. doi: 10.52711/0974-360X.2023.00376
- Kharisma VD et al. Garcinoxanthones from *Garcinia mangostana* L. against SARS-CoV-2 infection and cytokine storm pathway inhibition: A viroinformatics study. *Journal of Pharmacy and Pharmacognosy Research*. 2023; 11(5): 743-56. doi: 10.56499/jppres23.1650_11.5.743
- Novianti TE et al. The effect of low-fiber diets on colorectal cancer incidence in Southeast and East Asia: Systematic review and meta-analysis. *The Indonesian Journal of Public Health*. 2023 Aug 1;18(2):353–65. doi: 10.20473/ijph.v18i2.2023.353-365.
- Ho Y et al. Anticancer Effect of Citrus hystrix DC. Leaf Extract and Its Bioactive Constituents Citronellol and Citronellal on Triple Negative Breast Cancer MDA-MB-231 Cell Line. *Pharmaceuticals*. 2020; 13(12): 476. doi: 10.3390/ph13120476
- de Luna FCF et al. Anticancer Potential of Flavonoids: An Overview with an Emphasis on Tangeretin. *Pharmaceuticals*. 2023; 16(9):1229. doi: 10.3390/ph16091229
- Ho S-C, Kuo C-T. Hesperidin, nobiletin, and tangeretin are collectively responsible for the anti-neuroinflammatory capacity of tangerine peel (*Citrus reticulata* pericarpium). *Food and Chemicals Toxicology*. 2014; 71: 176-82. doi: 10.1016/j.fct.2014.06.014
- Herdiana N et al. Identification of Bioactive Compounds and Antibacterial Activity of Limeberry (*Triphasia trifolia*) Fruit Ethanol Extract against *Staphylococcus aureus*. *Tropical Journal of Natural Product Research*. 2024; 8(1): 5820-4. doi: 10.26538/tjnpr/v8i1.16
- Chen M-H et al. Traditional Small-Size Citrus from Taiwan: Essential Oil Bioactive Compounds and Antioxidants Capacity. *Medicines*. 2017; 4(2): 28. doi: 10.3390/medicines4020028
- Alrhoun S, Sennikov S. The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions. *Cancers*. 2022; 14(24): 6173. doi: 10.3390/cancers14246173
- Biri-Kovács B et al. Structure-Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Therapy. *Biomolecules*. 2020; 10(2): 183. doi: 10.3390/biom10020183
- Raghav KOS, Moasser MM. Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. *Clinical Cancer Therapy*. 2023; 29(13): 2351-61. doi: 10.1158/1078-0432.CCR-22-0283
- Nami B, Maadi H, Wang Z. Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer. *Cancers*. 2018; 10(10): 342. doi: 10.3390/cancers10100342
- Jiang N et al. Novel Treatment Strategies for Patients with HER2-Positive Breast Cancer Who Do Not Benefit from Current Targeted Therapy Drugs (Review). *Experimental and Therapeutic Medicine*. 2018; 16(3): 2183-92. doi: 10.3892/etm.2018.6459
- Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signalling Pathways. *Cancers*. 2017; 9(5): 52. doi: 10.3390/cancers9050052
- Khotimah S et al. Anti-Atherosclerotic Activity of Eleutherine americana Merr. as the Peroxisome Proliferated-Activated Receptor γ Agonist: In Silico Study. *Research Journal of Pharmacy and Technology*. 2020; 13(3): 1423-8. doi: 10.5958/0974-360X.2020.00260.7
- Banerjee P et al. ProTox 3.0: a webserver for the prediction of toxicity of chemicals. *Nucleic Acid Research*. 2024; 52(W1): 513-20. doi: 10.1093/nar/gkac303
- Daina A et al. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Scientific Reports*. 2017; Mar 3; 7(42717): 1-13. doi: 10.1038/srep42717
- O'Shaughnessy J et al. Risk of Recurrence in Patients with HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics. *Clinical Breast Cancer*. 2023; Mar 21; 23(4): 350-62. doi: 10.1016/j.clbc.2023.03.007
- Cheng X. A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. *Genes*. 2024; 15(7): 903. doi: 10.3390/genes15070903
- Swain SM et al. Targeting HER2-positive breast cancer: advances and future directions. *Nature Reviews Drug Discovery*. 2022 Nov 7; 22(2): 101-26. doi: 10.1038/s41573-022-00579-0
- Agu PC et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. *Scientific Reports*. 2023; Aug 17; 13(13398): 1-18. doi: 10.1038/s41598-023-40160-2
- Upgrade A et al. In silico Analysis on non-Structural Protein (NS4b) from DENV-2 Indian Strain for Antiviral Drug Discovery. *Research Journal of Pharmacy and Technology*. 2017; Dec 28; 11(4): 1671-6. doi: 10.5958/0974-360X.2018.00311.6
- Pantsar T, Poso A. Binding Affinity via Docking: Fact and Fiction. *Molecules*. 2018; Jul 30; 23(8): 1899. doi:

- 10.3390/molecules23081899
33. Tungary E et al. Molecular Docking of Active Compounds from Traditional Medicinal Plants as ACE-2 protein (1R4L) inhibitor in searching for COVID-19 drug. *Research Journal of Pharmacy and Technology*. 2022; Jan 17; 15(9): 4235-40. doi: 10.52711/0974-360X.2022.00712
 34. Praditapuspa EN et al. In Silico Analysis of Pinostrobin Derivatives from Boesenbergia pandurata on ErbB4 Kinase Target and QSPR Linear Models to Predict Drug Clearance for Searching Anti-Breast Cancer Drug Candidates. *Pharmacognosy Journal*. 2021; Jul 30; 13(5): 1143-9. doi: 10.5530/pj.2021.13.147
 35. Rahman AT et al. In Silico Study of the Potential of Endemic Sumatra Wild Turmeric Rhizomes (Curcuma Sumatrana: Zingiberaceae) As Anti-Cancer. *Pharmacognosy Journal*. 2022; Dec 5; 14(6): 806-12. doi: 10.5530/pj.2022.14.171
 36. Yadav AR, Mohite SK. ADME Analysis of Phytochemical Constituents of Psidium guajava. *Asian Journal of Research in Chemistry*. 2020; Jul 16; 13(5): 373-5. doi: 10.5958/0974-4150.2020.00070.X
 37. Adsule PV et al. Designing of Coumarin molecules as EGFR inhibitors and their ADMET, MD Simulation Studies for Evaluating potential as Anticancer molecules. *Research Journal of Pharmacy and Technology*. 2023; Sep 1; 17(3): 1008-14. doi: 10.52711/0974-360X.2024.00156
 38. Alfiansyah MRT et al. QSAR of Acyl Alizarin Red Biocompound Derivatives of Rubia tinctorum Roots and Its ADMET Properties as Anti-Breast Cancer Candidates Against MMP-9 Protein Receptor: In Silico Study. *Food Systems*. 2024; Jun 25; 7(2): 312-20. doi: 10.21323/2618-9771-2024-7-2-312-320